C07K 14/82
Translation products from oncogenes
C07K14/82 (Translation products from oncogenes) appears on 1,457 US grants and 2,430 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,457
- Published applications
- 2,430
- Assignees
- 713
- Inventors
- 2,801
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 3 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 13 | 0 |
| 1993 | 11 | 0 |
| 1994 | 18 | 0 |
| 1995 | 11 | 0 |
| 1996 | 43 | 0 |
| 1997 | 55 | 0 |
| 1998 | 80 | 0 |
| 1999 | 70 | 0 |
| 2000 | 57 | 0 |
| 2001 | 63 | 8 |
| 2002 | 48 | 77 |
| 2003 | 36 | 1129 |
| 2004 | 37 | 116 |
| 2005 | 33 | 80 |
| 2006 | 42 | 107 |
| 2007 | 178 | 58 |
| 2008 | 164 | 71 |
| 2009 | 43 | 61 |
| 2010 | 44 | 45 |
| 2011 | 34 | 45 |
| 2012 | 22 | 35 |
| 2013 | 22 | 22 |
| 2014 | 17 | 33 |
| 2015 | 26 | 36 |
| 2016 | 18 | 37 |
| 2017 | 20 | 41 |
| 2018 | 22 | 47 |
| 2019 | 35 | 44 |
| 2020 | 33 | 50 |
| 2021 | 34 | 43 |
| 2022 | 32 | 67 |
| 2023 | 20 | 49 |
| 2024 | 21 | 52 |
| 2025 | 31 | 45 |
| 2026 | 10 | 32 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and compositions for the expression of constitutively active RAP1A from a VMD2 promoter25 Aug 2026US 12,714,757 B2University of Flordia Research Foundation, Inc.
- T cell receptors recognizing HLA-CW8 restricted mutated KRAS7 Jul 2026US 12,673,981 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions19 May 2026US 12,629,375 B2Board of Regents, The University of Texas System
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies24 Mar 2026US 12,584,138 B2ImmunityBio, Inc.
- KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto17 Mar 2026US 12,577,278 B2Emory University
- Omomyc and kras inhibitors combination therapy for the treatment of cancer24 Sep 2026US 2026/0285945 A1Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron
- Compositions, Methods, And Systems For Targeting And Destabilizing RNA Transcripts (OVAC)3 Sep 2026US 2026/0258114 A1UTR Therapeutics Inc.
- Fusion neoantigens for use in cancer vaccines, antibody therapy, and cell therapies27 Aug 2026US 2026/0250358 A1The Cleveland Clinic Foundation
- Tcr molecule targeting kras g12v mutation, cell, and uses thereof27 Aug 2026US 2026/0250388 A1Beijing Dcty Biotech Co., Ltd.
- Tcr molecules targeting kras mutation, cells and use of tcr molecules and cells20 Aug 2026US 2026/0240907 A1Beijing Dcty Biotech Co., Ltd.
Most cited
By later US patents
- Compounds and methods for site directed mutations in eukaryotic cells460US 5,565,350 AThomas Jefferson University · 1996
- Method and apparatus for in vivo electroporation of remote cells and tissue353US 5,389,069 AMassachusetts Institute of Technology · 1995
- In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny316US 5,750,376 ANeurospheres Holdings Ltd. · 1998
- In vitro growth and proliferation of multipotent neural stem cells and their progeny265US 5,851,832 ANeurospheres, Ltd. · 1998
- Method for selection of proteins using RNA-protein fusions262US 6,258,558 B1The General Hospital Corporation · 2001